The company was founded in 1997 and is a modern high-tech enterprise integrating GAP cultivation of medicinal herbs, pharmaceutical production, R&D, sales and pharmaceutical logistics as its core industries. In 2016, it entered the “Top 100 Enterprises in Shaanxi” and was listed on A-shares on the Shenzhen Stock Exchange in November 2017. From 2018 to 2022, it has been on the list of China's top 100 pharmaceutical industry for five consecutive years. The company is a modern high-tech enterprise integrating standardized cultivation of medicinal herbs, pharmaceutical production, R&D, sales, and pharmaceutical logistics as its core industries. The main products are Panlong 7 tablets, white peony total glycosides capsules, paralysis capsules, paralysis tablets, Panlong 7 medicinal liquor, bone pine treasure tablets, Jinyinli Gall capsules, Kibi hot tablets, compound cotton phenol acetate tablets, motherwort granules, Shenling Baishu San, children's maizou chewable tablets, pediatric pharyngeal flat granules, bone gum Guizhen tablets, coenzyme Q10, chondroitin sulfate calcium tablets, melatonin tablets, Ganoderma lucidum spore powder, Panlong Qi Cream, Panlong Moisturizing and Repairing Mask, Panlong Astragalus, Pueraria Konjac Health Mask, Panlong Astragalus Tea, Panlong Seven Joint Health Care, Acupoint Stimulation Patch, etc. Corporate honors: AAA credit customers; model taxpayers; science and technology demonstration enterprises; AAA enterprises with quality service reputation in China; famous trademarks in Shaanxi Province; high-tech enterprises, etc. For many years in a row, it has been honored as a “Chinese Household Medication List Brand” product, a “Recommended Consumer Brand in the Traditional Chinese Medicine Market” product, and an “Ingenious Product”. The company won the 6th China Excellent IR “Best Shareholder Relationship Award” and won the honor of “2022 Excellent Investor Relations Management Unit”.
No Data